BLUEJET Share Price Performance
₹538.50
-14.40 (-2.60%)
24.6% undervalued intrinsic discount
₹714.17
Fair Value
Price ₹538.50
AnalystConsensusTarget ₹714.17
AnalystHighTarget ₹1,100.00
AnalystLowTarget ₹730.00
Fair Value₹714.17
Share Pricen/a
Blue Jet Healthcare Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
BLUEJET Community Narratives
AN
Fair Value ₹714.17 24.6% undervalued intrinsic discount
Analysts Lower Blue Jet Healthcare Valuation as Revenue Growth Projections Moderate Amid Company Updates
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value ₹1.1k 51.0% undervalued intrinsic discount
Aging Populations And Chronic Disease Will Feed Indian Pharma Outsourcing
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ₹730 26.2% undervalued intrinsic discount
Escalating Regulatory And Supply Risks Will Weaken Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Analysts Lower Blue Jet Healthcare Valuation as Revenue Growth Projections Moderate Amid Company Updates
Key Takeaways Expansion into high-margin specialties and backward integration enhances Blue Jet's cost efficiency, product portfolio, and margin stability. Strong global pharma trends and long-term client relationships support robust, sustained demand and recurring earnings growth.Read more
102
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
₹714.17
24.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
17.16% p.a.
Profit Margin
25.19%
Future PE
36.87x
Price in 2028
₹1.02k
Aging Populations And Chronic Disease Will Feed Indian Pharma Outsourcing
Key Takeaways Large-scale capacity expansion, supply chain independence, and innovative R&D position Blue Jet for significant margin and revenue growth beyond current market expectations. Strategic investments and a strong pipeline in high-demand segments give Blue Jet a defensible edge and upside from long-term demand and global supply shifts.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹1.1k
51.0% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
23.48% p.a.
Profit Margin
22.88%
Future PE
51.5x
Price in 2028
₹1.57k
Escalating Regulatory And Supply Risks Will Weaken Outlook
Key Takeaways Margin and earnings growth are threatened by global regulatory pressures, environmental compliance costs, and increased supply chain risks linked to emerging market dependencies. Heavy reliance on a concentrated customer base and lagging technological adaptation heighten the risk of revenue volatility and competitive disadvantages.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹730
26.2% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
13.33% p.a.
Profit Margin
28.95%
Future PE
34.97x
Price in 2028
₹1.04k
Trending Discussion
Recently Updated Narratives
AN
BLUEJET: Stable Earnings Outlook Will Support Dividend Income Ahead
Fair Value: ₹714.17 24.6% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Escalating Regulatory And Supply Risks Will Weaken Outlook
Fair Value: ₹730 26.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Chronic Disease Will Feed Indian Pharma Outsourcing
Fair Value: ₹1.1k 51.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Blue Jet Healthcare Limited Key Details
About BLUEJET
- Founded
- 1968
- Employees
- 196
- CEO
- WebsiteView website
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
